Hyppää sisältöön
    • Suomeksi
    • In English
  • Suomeksi
  • In English
  • Kirjaudu
Näytä aineisto 
  •   Etusivu
  • 3. UTUCris-artikkelit
  • Rinnakkaistallenteet
  • Näytä aineisto
  •   Etusivu
  • 3. UTUCris-artikkelit
  • Rinnakkaistallenteet
  • Näytä aineisto
JavaScript is disabled for your browser. Some features of this site may not work without it.

Time to abandon routine urine analysis prior to Bacillus Calmette–Guérin administration in asymptomatic patients

Nummi, Antti; Nurminen, Pertti; Kesti, Olli; Högerman, Mikael; Ettala, Otto; Boström, Peter J.; Kaipia, Antti; Sairanen, Jukka; Järvinen, Riikka

Time to abandon routine urine analysis prior to Bacillus Calmette–Guérin administration in asymptomatic patients

Nummi, Antti
Nurminen, Pertti
Kesti, Olli
Högerman, Mikael
Ettala, Otto
Boström, Peter J.
Kaipia, Antti
Sairanen, Jukka
Järvinen, Riikka
Katso/Avaa
BJUI Compass - 2025 - Nummi - Time to abandon routine urine analysis prior to Bacillus Calmette Gu rin administration in.pdf (1.123Mb)
Lataukset: 

Wiley
doi:10.1002/bco2.70117
URI
https://doi.org/10.1002/bco2.70117
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe202601216385
Tiivistelmä

Objective

This study aims to determine whether asymptomatic bacteriuria (ABU) increases the risk of infective complications requiring hospitalisation in patients undergoing Bacillus Calmette-Guérin (BCG) instillations and consequently evaluate the need to screen asymptomatic patients for bacteriuria prior to BCG administration.

Subjects/patients and methods

We analysed retrospectively all patients who received ≥1 BCG instillations as treatment of NMIBC in Helsinki University Hospital and Turku University Hospital during 2009–2018. Patients submitted urine specimens 1–7 days prior to every BCG instillation. Urine culture results and possible antibiotic prophylaxis prior to BCG administration were recorded. ABU was classified as having a positive urine culture but no dysuria or fever. All hospital admissions because of urinary tract infections and other BCG-related adverse effects within 2 weeks of BCG administration were recorded.

Results

We analysed 802 patients and 12 968 BCG instillations. ABU was recorded prior to 2428 (19%) instillations among which antibiotics were used in 527 (22%). Hospital admission was recorded after 9 (0,3%) and 39 (0,4%) instillations in the ABU and in the sterile urine groups, respectively (P = 0.9). Antibiotic prophylaxis did not affect the hospital admission rate (P = 0.2).

Conclusion

BCG instillation with ABU is safe, and the results do not support routine screening of asymptomatic patients for bacteriuria prior to intravesical BCG immunotherapy.

Kokoelmat
  • Rinnakkaistallenteet [29335]

Turun yliopiston kirjasto | Turun yliopisto
julkaisut@utu.fi | Tietosuoja | Saavutettavuusseloste
 

 

Tämä kokoelma

JulkaisuajatTekijätNimekkeetAsiasanatTiedekuntaLaitosOppiaineYhteisöt ja kokoelmat

Omat tiedot

Kirjaudu sisäänRekisteröidy

Turun yliopiston kirjasto | Turun yliopisto
julkaisut@utu.fi | Tietosuoja | Saavutettavuusseloste